688062 迈威生物
已收盘 05-08 15:00:01
资讯
新帖
简况
迈威生物9MW5211注射液治疗炎症性肠病临床试验申请获FDA正式批准
美股速递 · 05-08 22:55
迈威生物9MW5211注射液治疗炎症性肠病临床试验申请获FDA正式批准
迈威生物(688062.SH)：9MW5211注射液临床试验申请获得FDA许可
智通财经网 · 05-08 18:15
迈威生物(688062.SH)：9MW5211注射液临床试验申请获得FDA许可
迈威生物拟向交易商协会申请注册发行定向债务融资工具，规模不超10亿元
美股速递 · 05-06
迈威生物拟向交易商协会申请注册发行定向债务融资工具，规模不超10亿元
迈威生物-B(02493)拟申请注册发行规模不超过10亿元的定向债务融资工具
智通财经 · 05-06
迈威生物-B(02493)拟申请注册发行规模不超过10亿元的定向债务融资工具
迈威生物-B早盘一度涨超23%创新高 公司已推动4款产品获批上市
新浪港股 · 04-30
迈威生物-B早盘一度涨超23%创新高 公司已推动4款产品获批上市
港股异动 | 迈威生物-B(02493)最高涨超23% 9MW2821用于宫颈癌临床研究结果将于2026 ESMO GC公布
智通财经 · 04-30
港股异动 | 迈威生物-B(02493)最高涨超23% 9MW2821用于宫颈癌临床研究结果将于2026 ESMO GC公布
迈威生物（688062）2026年一季报简析：营收上升亏损收窄
证券之星 · 04-30
迈威生物（688062）2026年一季报简析：营收上升亏损收窄
迈威生物2026年第一季度净亏损2.42亿元
北京商报 · 04-28
迈威生物2026年第一季度净亏损2.42亿元
深港通下的港股通标的证券名单调入迈威生物-B，今日起生效
老虎资讯综合 · 04-28
深港通下的港股通标的证券名单调入迈威生物-B，今日起生效
【新股IPO】迈威生物-Ｂ(02493)一手中签率为1.00% 认购倍数约481.71倍
金吾财讯 · 04-28
【新股IPO】迈威生物-Ｂ(02493)一手中签率为1.00% 认购倍数约481.71倍
上交所：将迈威生物-B(02493)调入沪港通下的港股通标的
智通财经 · 04-27
上交所：将迈威生物-B(02493)调入沪港通下的港股通标的
每周股票复盘：迈威生物（688062）H股发行价区间27.64-30.71港元
证券之星 · 04-26
每周股票复盘：迈威生物（688062）H股发行价区间27.64-30.71港元
迈威生物（688062）披露2025年年度股东会增加香港会议地址公告，4月23日股价下跌5.44%
证券之星 · 04-23
迈威生物（688062）披露2025年年度股东会增加香港会议地址公告，4月23日股价下跌5.44%
迈威生物启动Nectin-4靶向ADC药物9MW2821治疗三阴性乳腺癌的III期临床研究
美股速递 · 04-23
迈威生物启动Nectin-4靶向ADC药物9MW2821治疗三阴性乳腺癌的III期临床研究
卡位ADC、TCE前沿赛道，迈威生物(02493)港股IPO含金量有几分？
智通财经 · 04-20
卡位ADC、TCE前沿赛道，迈威生物(02493)港股IPO含金量有几分？
迈威生物（2493.HK）：Nectin-4 ADC领跑，ST2单抗蓄势，多领域布局下的价值图谱
格隆汇 · 04-20
迈威生物（2493.HK）：Nectin-4 ADC领跑，ST2单抗蓄势，多领域布局下的价值图谱
迈威生物-B(02493)今起招股 君实生物、桂林三金及药明生物等基石认购5300万美元发售股份
智通财经 · 04-20
迈威生物-B(02493)今起招股 君实生物、桂林三金及药明生物等基石认购5300万美元发售股份
迈威生物-B(02493)4月20至23日招股 拟全球发售4713.02万股H股
智通财经 · 04-20
迈威生物-B(02493)4月20至23日招股 拟全球发售4713.02万股H股
每周股票复盘：迈威生物（688062）两款新药临床申请获受理
证券之星 · 04-19
每周股票复盘：迈威生物（688062）两款新药临床申请获受理
迈威生物与马来西亚市场就地舒单抗生物类似药达成授权及商业化协议
美股速递 · 04-16
迈威生物与马来西亚市场就地舒单抗生物类似药达成授权及商业化协议
加载更多
公司概况
公司名称：
迈威(上海)生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2022-01-18
主营业务：
迈威(上海)生物科技股份有限公司的主营业务是研发、生产以及销售创新型药物和生物类似药。公司的主要产品是抗体、ADC药物和重组蛋白、小分子化学药等药物。
发行价格：
34.80
{"stockData":{"symbol":"688062","market":"SH","secType":"STK","nameCN":"迈威生物","latestPrice":35.16,"timestamp":1778223601000,"preClose":35.58,"halted":0,"volume":9415731,"delay":0,"changeRate":-0.0118,"floatShares":204000000,"shares":447000000,"eps":-2.0584,"marketStatus":"已收盘","change":-0.42,"latestTime":"05-08 15:00:01","open":35.3,"high":35.81,"low":34.11,"amount":328000000,"amplitude":0.0478,"askPrice":35.16,"askSize":3,"bidPrice":35.11,"bidSize":229,"shortable":0,"etf":0,"ttmEps":-2.0584,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778463000000},"marketStatusCode":5,"adr":0,"adjPreClose":35.58,"symbolType":"stock_kcb","openAndCloseTimeList":[[1778203800000,1778211000000],[1778216400000,1778223600000]],"highLimit":39.14,"lowLimit":32.02,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":446730200,"isCdr":false,"pbRate":147.05,"roa":"--","roe":"--","epsLYR":-2.43,"committee":0.023853,"marketValue":15707000000,"turnoverRate":0.0461,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-05-11。","afterMarket":{"amount":0,"volume":0,"close":35.16,"buyVolume":0,"sellVolume":0,"time":1778225637558,"indexStatus":"已收盘 05-08 15:30:00","preClose":35.58},"hkstockBrief":{"symbol":"02493","market":"HK","secType":"STK","nameCN":"迈威生物-B","latestPrice":26.58,"timestamp":1778227681656,"preClose":26.54,"halted":0,"volume":891800,"delay":0,"premium":"-34.36"},"floatMarketCap":7179000000},"requestUrl":"/m/hq/s/688062","defaultTab":"news","newsList":[{"id":"1154828404","title":"迈威生物9MW5211注射液治疗炎症性肠病临床试验申请获FDA正式批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1154828404","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154828404?lang=zh_cn&edition=full","pubTime":"2026-05-08 22:55","pubTimestamp":1778252116,"startTime":"0","endTime":"0","summary":"迈威生物（上海）股份有限公司宣布，其研发的9MW5211注射液用于治疗炎症性肠病的临床试验申请，已获得美国食品药品监督管理局（FDA）的正式批准。这一进展标志着该药物在海外临床开发方面迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633432532","title":"迈威生物(688062.SH)：9MW5211注射液临床试验申请获得FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2633432532","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633432532?lang=zh_cn&edition=full","pubTime":"2026-05-08 18:15","pubTimestamp":1778235339,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物 发布公告，公司收到美国食品药品监督管理局签发的《临床研究继续进行通知书》，，9MW5211注射液用于炎症性肠病适应症的临床试验申请正式获得FDA许可，同时，其用于IBD和多发性硬化等多个适应症的临床试验申请已获得国家药品监督管理局受理，公司亦在积极推进其他适应症临床试验申请工作。通过选择性识别并清除这群致病性细胞，9MW5211可有效阻断免疫级联反应，进而缓解疾病进展并改善临床症状。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","BK0239","02493","BK4588","BK4585","LABU","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134132557","title":"迈威生物拟向交易商协会申请注册发行定向债务融资工具，规模不超10亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1134132557","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134132557?lang=zh_cn&edition=full","pubTime":"2026-05-06 22:36","pubTimestamp":1778078171,"startTime":"0","endTime":"0","summary":"迈威生物宣布，公司计划向中国银行间市场交易商协会提交申请，拟注册发行定向债务融资工具。本次发行的总规模将不超过人民币10亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633131510","title":"迈威生物-B(02493)拟申请注册发行规模不超过10亿元的定向债务融资工具","url":"https://stock-news.laohu8.com/highlight/detail?id=2633131510","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633131510?lang=zh_cn&edition=full","pubTime":"2026-05-06 22:09","pubTimestamp":1778076591,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物-B(02493)发布公告，为进一步优化债务结构，拓宽公司融资渠道，降低公司财务成本，根据公司战略发展规划及资金需求，公司拟向中国银行间市场交易商协会申请注册发行规模不超过10亿元(含10亿元)的定向债务融资工具。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438774.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02493","688062","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631702570","title":"迈威生物-B早盘一度涨超23%创新高 公司已推动4款产品获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2631702570","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631702570?lang=zh_cn&edition=full","pubTime":"2026-04-30 11:31","pubTimestamp":1777519860,"startTime":"0","endTime":"0","summary":" 迈威生物-B最高涨超23%，触及31.46港元，创上市新高。截至发稿，涨7.22%，报27.32港元，成交额1.84亿港元。自成立以来，公司已推动4款产品获批上市，实现4款创新品种的对外授权。 值得关注的是，迈威生物昨日宣布将于当地时间2026年6月17–19日在丹麦哥本哈根举行的2026 欧洲肿瘤内科学妇科肿瘤年会分别以口头报告和壁报形式公布靶向 Nectin-4 ADC 创新药 9MW2821 用于宫颈癌的两项最新临床研究结果。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-04-30/doc-inhwfyeh7154434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IPOS","BK1161","688062","02493","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631357717","title":"港股异动 | 迈威生物-B(02493)最高涨超23% 9MW2821用于宫颈癌临床研究结果将于2026 ESMO GC公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2631357717","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631357717?lang=zh_cn&edition=full","pubTime":"2026-04-30 10:48","pubTimestamp":1777517308,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，迈威生物-B最高涨超23%，触及31.46港元创上市新高。值得关注的是，迈威生物昨日宣布将于当地时间2026年6月17–19日在丹麦哥本哈根举行的2026 欧洲肿瘤内科学妇科肿瘤年会分别以口头报告和壁报形式公布靶向 Nectin-4 ADC 创新药 9MW2821 用于宫颈癌的两项最新临床研究结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"54a3c0ad0e347d9e6f95c7a6e00c2a09","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","688062","BK0239","BK1161","02493","BK4585","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631557899","title":"迈威生物（688062）2026年一季报简析：营收上升亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2631557899","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631557899?lang=zh_cn&edition=full","pubTime":"2026-04-30 06:52","pubTimestamp":1777503142,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期迈威生物发布2026年一季报。根据财报显示，迈威生物营收上升亏损收窄。截至本报告期末，公司营业总收入1.28亿元，同比上升184.89%，归母净利润-2.42亿元，同比上升17.07%。本次财报公布的各项数据指标表现尚佳。持有迈威生物最多的基金为易方达医药生物股票A，目前规模为19.96亿元，最新净值0.8025，较上一交易日下跌0.86%，近一年上涨13.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000023699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630025983","title":"迈威生物2026年第一季度净亏损2.42亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630025983","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630025983?lang=zh_cn&edition=full","pubTime":"2026-04-28 20:24","pubTimestamp":1777379083,"startTime":"0","endTime":"0","summary":"北京商报讯（记者王寅浩宋雨盈）4月28日，迈威生物发布2026年第一季度报告，报告期内，公司实现营业收入1.28亿元，同比增长184.89%；归属于上市公司股东的净亏损为2.42亿元，上年同期为亏损2.92亿元；归属于上市公司股东的扣除非经常性损益的净亏损为2.42亿元，上年同期为亏损2.93亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604283722717414.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604283722717414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688062","02493","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102446045","title":"深港通下的港股通标的证券名单调入迈威生物-B，今日起生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1102446045","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102446045?lang=zh_cn&edition=full","pubTime":"2026-04-28 08:43","pubTimestamp":1777337012,"startTime":"0","endTime":"0","summary":"深交所公告，港股通标的证券名单发生调整并自2026年04月28日起生效，调入迈威生物-B。","market":"us","thumbnail":"https://static.tigerbbs.com/d297f5a820fb53702316973cf4f4f6d5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/d297f5a820fb53702316973cf4f4f6d5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"07bac0175d858e54df48541d68aa044c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630031601","title":"【新股IPO】迈威生物-Ｂ(02493)一手中签率为1.00% 认购倍数约481.71倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2630031601","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630031601?lang=zh_cn&edition=full","pubTime":"2026-04-28 01:03","pubTimestamp":1777309406,"startTime":"0","endTime":"0","summary":"金吾财讯 | 迈威生物-Ｂ 刊发全球发售配发结果公告，最终发售价厘定为每股27.64港元，股份将于2026年4月28日于港交所主板挂牌上市，每手买卖单位为200股。本次全球发售合共4713.02万股H股，其中香港公开发售4,713,200股，占全球发售10%；国际发售42,417,000股，占比90%。香港公开发售获大幅超额认购，有效申请126,378份，认购倍数约481.71倍，一手中签率为1.00%。国际发售获适度超额认购，认购倍数约3.46倍，承配人共82名。本次IPO未授出超额配售选择权。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/Nzc3MzgwMzMzMzM4NGQyNThhOGYxYzk1ZjFmM2VmN2U1NDI1NjgyMzc0Ng==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/Nzc3MzgwMzMzMzM4NGQyNThhOGYxYzk1ZjFmM2VmN2U1NDI1NjgyMzc0Ng==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980059","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688062","BK0239","SPCX","IPOS","BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630394291","title":"上交所：将迈威生物-B(02493)调入沪港通下的港股通标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2630394291","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630394291?lang=zh_cn&edition=full","pubTime":"2026-04-27 21:09","pubTimestamp":1777295366,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月27日，上海证券交易所发布关于沪港通下港股通标的调整的通知。因上海证券交易所上市公司迈威生物(688062.SH)在香港联合交易所有限公司上市H股迈威生物-B(02493)，其H股不适用价格稳定期机制，且相应A股上市满10个交易日，根据《上海证券交易所沪港通业务实施办法》的有关规定，沪港通下港股通(以下简称港股通)标的名单发生调整，调入迈威生物-B(02493)，并自下一港股通交易日起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4588","BK4585","688062","02493","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630801260","title":"每周股票复盘：迈威生物（688062）H股发行价区间27.64-30.71港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630801260","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630801260?lang=zh_cn&edition=full","pubTime":"2026-04-26 02:51","pubTimestamp":1777143068,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，迈威生物报收于37.2元，较上周的38.77元下跌4.05%。本周关注点公司公告汇总：迈威生物H股发行价格区间为27.64港元至30.71港元，预计2026年4月28日挂牌上市。公司公告汇总迈威生物关于刊发H股招股说明书、H股发行价格区间及H股香港公开发售等事宜的公告迈威（上海）生物科技股份有限公司于2026年4月20日在香港联交所网站刊登H股招股说明书，并刊发H股发行价格区间为27.64港元至30.71港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600001070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629885897","title":"迈威生物（688062）披露2025年年度股东会增加香港会议地址公告，4月23日股价下跌5.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629885897","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629885897?lang=zh_cn&edition=full","pubTime":"2026-04-23 22:22","pubTimestamp":1776954142,"startTime":"0","endTime":"0","summary":"截至2026年4月23日收盘，迈威生物报收于38.1元，较前一交易日下跌5.44%，最新总市值为152.25亿元。该股当日开盘40.25元，最高40.25元，最低37.41元，成交额达4.17亿元，换手率为5.33%。近日，迈威（上海）生物科技股份有限公司发布《关于2025年年度股东会增加会议地址的公告》。会议审议事项包括2025年年度报告、利润分配方案、续聘审计机构等议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300062524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117070579","title":"迈威生物启动Nectin-4靶向ADC药物9MW2821治疗三阴性乳腺癌的III期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1117070579","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117070579?lang=zh_cn&edition=full","pubTime":"2026-04-23 16:17","pubTimestamp":1776932235,"startTime":"0","endTime":"0","summary":"迈威生物（股票代码：688062）正式启动其创新药物9MW2821的III期临床试验。该药物是一款靶向Nectin-4的抗体偶联物（ADC），本次研究旨在评估其在治疗三阴性乳腺癌（TNBC）患者中的疗效与安全性。\n此举标志着该核心在研产品从中期临床向确证性临床研究迈出了关键一步，为后续的新药申报上市奠定了坚实基础。III期临床研究的开启，也体现了公司在ADC抗肿瘤药物研发领域的重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628790385","title":"卡位ADC、TCE前沿赛道，迈威生物(02493)港股IPO含金量有几分？","url":"https://stock-news.laohu8.com/highlight/detail?id=2628790385","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628790385?lang=zh_cn&edition=full","pubTime":"2026-04-20 09:40","pubTimestamp":1776649207,"startTime":"0","endTime":"0","summary":"2026年4月20日，迈威生物正式启动招股程序，中信证券与海通国际担任联席保荐人。在这一波创新药出海浪潮中，手握全球领先管线的迈威生物无疑将受到市场密切关注。通过ADC与TCE双平台驱动，叠加多元化的创新管线布局，迈威生物正在肿瘤治疗领域构建起差异化的强大竞争壁垒。从业绩来看，迈威生物已交出了一份颇具说服力的答卷：2024-","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02493","BK0239","BK4231","SPCX","BK4585","BK4080","ADC","688062","BK4588","IPOS","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628292792","title":"迈威生物（2493.HK）：Nectin-4 ADC领跑，ST2单抗蓄势，多领域布局下的价值图谱","url":"https://stock-news.laohu8.com/highlight/detail?id=2628292792","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628292792?lang=zh_cn&edition=full","pubTime":"2026-04-20 09:03","pubTimestamp":1776646985,"startTime":"0","endTime":"0","summary":"当A+H双平台为它打开新的资本窗口，当生物医药成为国家支柱产业的大势已经明朗，迈威生物已从一家biotech成长为能自己造血、自己生产、自己卖药的全产业链biopharma，未来值得期待。","market":"sg","thumbnail":"https://img2.gelonghui.com/d273d-800407fd-2249-448f-b352-5198e098082d.jpg?guru_height=855&guru_width=1280&guru_size=118253","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/d273d-800407fd-2249-448f-b352-5198e098082d.jpg?guru_height=855&guru_width=1280&guru_size=118253"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4463975","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4080","BK4231","688062","ADC","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628799412","title":"迈威生物-B(02493)今起招股 君实生物、桂林三金及药明生物等基石认购5300万美元发售股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2628799412","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628799412?lang=zh_cn&edition=full","pubTime":"2026-04-20 06:34","pubTimestamp":1776638067,"startTime":"0","endTime":"0","summary":"2025年8月，迈利舒及迈卫健获巴基斯坦药品监管局上市批准。迈利舒及迈卫健是在巴基斯坦获批的首个Prolia及Xgeva生物类似药。于2024年及2025年，净亏损分别为约10.47亿元及9.72亿元，主要由于研发活动所产生的成本及开支。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430395.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0979878070.USD","LU0856984785.SGD","LU0140636845.USD","LU1794554557.SGD","LU0326950275.SGD","BK1583","LU1720050803.USD","BK0060","LU0516423091.SGD","LU2039709279.SGD","01877","BK1161","BK1610","LU0456846285.SGD","LU0819121731.USD","002275","LU0307460666.USD","LU0348735423.USD","LU0572944931.SGD","LU0823426308.USD","BK1589","LU0327786744.USD","BK0188","02269","SG9999002562.SGD","LU0052750758.USD","LU0039217434.USD","LU0043850808.USD","LU0417516902.SGD","LU0051755006.USD","688062","LU0588546209.SGD","LU0417516738.SGD","BK0028","LU0456827905.SGD","LU0516422440.USD","LU0516423174.USD","LU0823426480.USD","LU1688375341.USD","LU1880383366.USD","LU1242518857.USD","SG9999002463.SGD","02493","LU0516422366.SGD","LU3063872942.SGD","BK0239","BK1515","BK1576","LU0181495838.USD","688180"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628799557","title":"迈威生物-B(02493)4月20至23日招股 拟全球发售4713.02万股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2628799557","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628799557?lang=zh_cn&edition=full","pubTime":"2026-04-20 06:17","pubTimestamp":1776637031,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物-B(02493)于2026年4月20至2026年4月23日招股，公司拟全球发售4713.02万股H股，香港公开发售占10%，国际发售占90%。每股发售价27.64-30.71港元，每手200股，预期H股将于香港时间2026年4月28日(星期二)上午九时正开始在联交所买卖。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628275697","title":"每周股票复盘：迈威生物（688062）两款新药临床申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2628275697","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628275697?lang=zh_cn&edition=full","pubTime":"2026-04-19 01:41","pubTimestamp":1776534069,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，迈威生物报收于38.77元，较上周的37.91元上涨2.27%。本周，迈威生物4月16日盘中最高价报41.0元。本周关注点公司公告汇总：注射用6MW5311临床试验申请获国家药监局受理公司公告汇总：迈卫健注射液新增适应症补充申请获国家药监局受理公司公告汇总注射用6MW5311用于血液瘤适应症的临床试验申请已获国家药品监督管理局受理。地舒单抗注射液增加实体肿瘤骨转移和多发性骨髓瘤适应症的补充申请已获国家药品监督管理局受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900000515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179745912","title":"迈威生物与马来西亚市场就地舒单抗生物类似药达成授权及商业化协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1179745912","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179745912?lang=zh_cn&edition=full","pubTime":"2026-04-16 17:05","pubTimestamp":1776330354,"startTime":"0","endTime":"0","summary":"迈威生物宣布，已就旗下地舒单抗生物类似药产品与马来西亚市场达成一项授权及商业化合作协议。该协议的签署标志着公司国际化战略在东南亚市场取得重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778403225314,"stockEarnings":[{"period":"1week","weight":-0.016},{"period":"1month","weight":-0.0922},{"period":"3month","weight":-0.0179},{"period":"6month","weight":-0.1721},{"period":"1year","weight":0.7109},{"period":"ytd","weight":-0.086}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0463},{"period":"3month","weight":0.0281},{"period":"6month","weight":0.0456},{"period":"1year","weight":0.247},{"period":"ytd","weight":0.0532}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"迈威(上海)生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"18977人(较上一季度增加2.21%)","perCapita":"10758股","listingDate":"2022-01-18","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路230号2幢105室","registeredCapital":"44673万元","survey":" 迈威(上海)生物科技股份有限公司的主营业务是研发、生产以及销售创新型药物和生物类似药。公司的主要产品是抗体、ADC药物和重组蛋白、小分子化学药等药物。","listedPrice":34.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迈威生物(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迈威生物(688062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迈威生物,688062,迈威生物股票,迈威生物股票老虎,迈威生物股票老虎国际,迈威生物行情,迈威生物股票行情,迈威生物股价,迈威生物股市,迈威生物股票价格,迈威生物股票交易,迈威生物股票购买,迈威生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迈威生物(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迈威生物(688062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}